Simon Quick Advisors LLC Buys 1,027 Shares of Amgen Inc. (NASDAQ:AMGN)

Simon Quick Advisors LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 34.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,022 shares of the medical research company's stock after acquiring an additional 1,027 shares during the quarter. Simon Quick Advisors LLC's holdings in Amgen were worth $1,253,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Beck Mack & Oliver LLC grew its stake in shares of Amgen by 0.7% in the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock worth $1,205,000 after acquiring an additional 34 shares in the last quarter. Continuum Advisory LLC boosted its holdings in shares of Amgen by 0.7% in the 4th quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock worth $1,343,000 after buying an additional 35 shares during the last quarter. Octavia Wealth Advisors LLC boosted its holdings in shares of Amgen by 1.5% in the 1st quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company's stock worth $759,000 after buying an additional 35 shares during the last quarter. Zullo Investment Group Inc. boosted its holdings in shares of Amgen by 2.8% in the 4th quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after buying an additional 37 shares during the last quarter. Finally, Trillium Asset Management LLC boosted its holdings in shares of Amgen by 4.2% in the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after buying an additional 37 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of Amgen stock traded down $2.07 on Friday, reaching $295.22. The stock had a trading volume of 2,191,182 shares, compared to its average volume of 2,820,660. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market cap of $158.74 billion, a P/E ratio of 39.10, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The business's 50 day moving average is $281.33 and its two-hundred day moving average is $285.62.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the prior year, the firm posted $3.96 earnings per share. The company's revenue for the quarter was up 9.4% on a year-over-year basis. As a group, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on AMGN. Cantor Fitzgerald began coverage on shares of Amgen in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price target on the stock. Mizuho boosted their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a report on Wednesday, May 7th. Morgan Stanley reissued an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Finally, Guggenheim began coverage on shares of Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Amgen currently has an average rating of "Hold" and an average target price of $309.22.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.76% of the company's stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.